KKR acquired Integer Holdings in an all-cash transaction valued at $5.7 billion, taking the medical-device contract manufacturer private and consolidating the firm's position in specialized healthcare manufacturing. The deal removes a publicly traded supplier with $1.5 billion in annual revenue from equity markets and places critical manufacturing capacity for cardiac rhythm management and neuromodulation devices under private-equity control.
Integer manufactures components and finished devices for implantable medical products—pacemakers, defibrillators, neurostimulators—serving customers including Medtronic, Abbott, and Boston Scientific. The company operates 17 facilities across nine countries, with approximately 40% of revenue derived from cardiac rhythm devices and 25% from neuromodulation. KKR's all-cash structure at approximately $94 per share represents a 32% premium to Integer's 30-day volume-weighted average price. The transaction is expected to close in the second half of 2025, subject to regulatory clearance and shareholder approval.
The acquisition extends KKR's healthcare manufacturing footprint beyond its existing holdings in PCI Pharma Services and Lifescience Dynamics. Integer's customer concentration—top five clients account for roughly 65% of revenue—creates negotiating leverage in a sector where switching costs for implantable-device suppliers run high due to regulatory validation timelines. Medical-device OEMs typically require 18-24 months to requalify alternative manufacturers, giving Integer pricing power and contract durability that align with KKR's operational playbook. The firm has flagged supply-chain resilience and margin expansion as value-creation levers, with Integer's adjusted EBITDA margins at approximately 18% trailing peers by 300-400 basis points.
This transaction fits a pattern of private-equity firms acquiring mid-tier healthcare suppliers with embedded customer bases and margin-optimization potential. KKR's timing capitalizes on Integer's relatively depressed public-market valuation—shares traded at 12.5x forward EBITDA before deal announcement—while the broader medical-device sector trades at 16-18x. The premium reflects not just operational upside but also strategic value in owning manufacturing capacity as device OEMs increasingly outsource production to manage capital intensity.
Operators should track three developments: regulatory filings expected in Q2 2025 for antitrust clearance, Integer's customer-retention announcements post-close, and KKR's margin-improvement timeline. Medical-device OEMs may accelerate dual-sourcing initiatives if they perceive ownership change as supply-chain risk. Watch for Integer's Q1 2025 earnings commentary on customer reactions and any contract renegotiations.
KKR now controls manufacturing infrastructure that touches approximately 12% of the global cardiac rhythm management device market. The firm owns not just a supplier but a chokepoint.